Olema Pharmaceuticals Inc
NASDAQ:OLMA
Olema Pharmaceuticals Inc
NASDAQ:OLMA
Price:
16.6
USD
12.85%
Market Closed
Market Cap:
$1.3B
Relative Value
The Relative Value of one
OLMA
stock under the Base Case scenario is
1.73
USD.
Compared to the current market price of 16.6 USD,
Olema Pharmaceuticals Inc
is
Overvalued by 90%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
OLMA
Relative Value
Base Case
1.73
USD
Overvaluation 90%
Multiples Across Competitors
OLMA Competitors Multiples
Olema Pharmaceuticals Inc Competitors
Olema Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Olema Pharmaceuticals Inc
NASDAQ:OLMA
|
1.3B USD | 0 | -8.4 | -5.7 | -5.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
391.5B USD | 6.4 | 93.5 | 15.4 | 21.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.4B USD | 5.4 | 25.6 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
180.2B USD | 6.1 | 21.2 | 13.2 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.4B USD | 9.9 | 29.9 | 22.6 | 23.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80B USD | 5.6 | 17.8 | 13.2 | 15.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.7B AUD | 3.1 | 34.6 | 11.4 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.7B EUR | 10.7 | 34.5 | 37.3 | 38.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
